

Editorial

Reducing Cholera Mortality and Incidence: Unfinished Business.

Dad Naln

Department of Medical Oncology, Sun Yat-sen University Cancer Center, China.

Significant progress has been achieved in the creation of novel cholera vaccines and vaccination prevention techniques. By creating vaccines with greater efficacy and longer duration of protection, particularly in young children and people from non-endemic areas, potential future objectives in this field could build on recent advancements. Additional vibrio antigen discovery could validate protective immune responses as surrogates of protection, a necessity brought on by evidence that the protective mechanism is not the usually seen viriocidal reaction, despite the fact that it parallels evidence of protection. Current obstacles, such as the incidence of cholera epidemics in war-torn countries where short-term vaccination campaigns sometimes prove unfeasible, could be overcome by such additional advancements. This series of articles presents the latest developments in cholera immunology, bioecology, vaccine development, and treatment, which have resulted in aggressive targets for reducing the disease's incidence and death, which still exists in afflicted areas. The conversation would not be complete without mentioning areas that might be useful for reaching the existing goals but are not prioritized or included in them.

First, the necessity for action to supply safe chlorinated drinking water and sanitary waste disposal to unserved areas is being discussed far too much and not enough. In order to provide sufficient funding for these crucial components of contemporary public health in both urban and rural areas, more work is needed to rethink national objectives. If the Global Task Force on Cholera Control is to have any hope of achieving its goal of eradicating cholera by 2030, international rules and laws controlling urban development in the era of global urbanization [1] are crucial. Second, the

causes and prevention of tropical hypochlorhydria, both nutritional and otherwise, have received little attention [2]. This condition is common in developing countries and makes people there more vulnerable to cholera and other gastric acid-sensitive infections. Eliminating tropical hypochlorhydria would probably significantly lower the incidence of cholera in impacted areas and possibly increase the protectiveness of vaccines, according to human volunteer studies [3], which showed that even large numbers of *V. cholerae* do not cause illness in normochlorhydric subjects. Third, the development of safe and efficient anti-cholera medications that can promptly halt cholera diarrhea has received far too little research money. Despite a wealth of information, no large screening of molecules likely to have such efficacy has been conducted. Numerous possible high-value targets are suggested by recent developments in cholera pathophysiology, such as the validation of VIP's involvement in human cholera [4], which warrant inclusion in such a screening effort in animal models that lead to clinical trials.

Last but not least, the persistently high cholera case-fatality rates in spite of proven, highly effective, and accessible treatment techniques necessitate a fresh emphasis on the gaps that keep therapy from reaching patients.

REFERENCES

1. Bollyky, T.J. Oral Rehydration Salts, Cholera, and the Unfinished Urban Health Agenda. *Trop. Med. Infect. Dis.* 2022, 7, 67. [CrossRef].

***Corresponding Author:** Dad Naln, Department of Medical Oncology, Sun Yat-sen University Cancer Center, China.

Received: 03-Feb-2025, ; **Editor Assigned:** 04-Feb-2025 ; **Reviewed:** 20-Feb-2025, ; **Published:** 27-Feb-2025.

Citation: Dad Naln. Reducing Cholera Mortality and Incidence: Unfinished Business. *Advances in Vaccines*. 2025 February; 1(1).

Copyright © 2025 Dad Naln. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

2. Nalin, D.R.; Levine, R.J.; Levine, M.M.; Hoover, D.; Bergquist, E.; McLaughlin, J.; Libonati, J.; Alam, J.; Hornick, R.B. Cholera, non-vibrio cholera and stomach acid. *Lancet* 1978, 2, 856–859. [CrossRef].
3. Cash, R.A.; Music, S.I.; Libonati, J.P.; Snyder, M.J.; Wenzel, R.P.; Hornick, R.B. Response of man to infection with *Vibrio cholerae*. I. Clinical, serologic, and bacteriologic responses to a known inoculum. *J. Infect. Dis.* 1974, 129, 45–52. [CrossRef] [PubMed].
4. Afroze, F.; Bloom, S.; Bech, P.; Ahmed, T.; Sarker, S.A.; Clemens, J.D.; Islam, F.; Nalin, D. Cholera and Pancreatic Cholera: Is VIP the Common Pathophysiologic Factor? *Trop. Med. Infect. Dis.* 2020, 5, 111. [CrossRef] [PubMed].